At 1.7x trailing sales with a record 54.5% gross margin and positive adjusted EBITDA — WATCHLIST rather than BUY because two consecutive guidance cuts reset growth from 35% to low-teens and the share count rose 72% in a year; the 10-year math clears the 10x aim from here, but wait for Owlet360 subscribers past 150k and a flat share count before committing capital.

At 6.8x trailing P/S following a 43% drawdown from its July 2025 high, with record free cash flow and 325M+ still-growing subscribers — WATCHLIST because professional (non-founder) leadership and a maturing growth curve keep the 10-year bull case just under the framework's multibagger bar; worth tracking through the July 16 earnings print, not building a core position today.

At 2.7x trailing sales — down ~43% from its August 2025 high after a ~55% peak-to-trough drawdown — with GAAP profitability achieved (21% Q1 operating margin) and ToastIQ AI lifting attach across 171,000 locations, the restaurant-software category leader is screened like a slowing payments processor while compounding recurring gross profit above 30%; BUY into the drawdown with sub-5x entry discipline now fully met, adding on any retest of the low-$20s.

At ~80x trailing sales with a powerful AI-data-center power tailwind and three structural AI-disruption anchors — WATCHLIST not BUY because the entry valuation already prices substantial success and the company is pre-commercial cash-burn; track for a Pattern B/E pullback toward $10–13 before the math turns asymmetric.

At 6.3x trailing P/S after a ~57% slide from its IPO high, with FY2025 revenue up 97%, positive free cash flow, and a molecular database rivals cannot replicate — WATCHLIST while the 2026 growth-deceleration guidance plays through; the 10-year bull case already clears the 10x aim at today's price, and a dip toward ~5x P/S (~$14–15, the 52-week low) would flip this to BUY.

At ~27x trailing P/S after a four-fold run in twelve months, with a near-duopoly in custom AI accelerators and 70–80% share in 800G optical DSPs — WATCHLIST because the price already prepays the bull case; re-engage on a Pattern B/E dip toward ~10x forward sales (~$130), where the 10-year math reopens toward the 10x aim.

At a ~$59M market cap after a 700% run, with only ~$15M cash and runway through 2026, MiNK is the sole listed pure-play in a genuinely differentiated iNKT modality — WATCHLIST: the off-the-shelf allo-iNKT science and early ARDS and gastric-cancer signals are real, but this is a venture-style micro-cap where a near-term dilutive raise is the dominant variable; wait for a post-raise reset or a Phase 2 readout rather than chasing the spike.

At a ~$319M market cap with $143M cash and a near-zero revenue base, Nautilus pairs a genuinely best-in-class proteomics instrument with a now-dated commercial launch — WATCHLIST: the Voyager platform was field-validated and opens for pre-orders in late 2026, but the entry is a binary bet on commercial scale-up with a financing round looming right as launch begins; revisit on confirmed Early-Access conversion or a post-raise reset.

At ~65x trailing sales (≈33x forward) on a founder-controlled balance sheet diluting ~28% a year — but as the only name in its cohort with an FDA-approved product and revenue up 700% — WATCHLIST: the IL-15 franchise is real and scaling, yet an oncology biologic that will mature to single-digit sales multiples cannot carry a 65x entry, holding even the 10-year bull case near 4x; revisit on a valuation reset toward ~$4 or a clean US FDA lung/pancreatic approval.

At ~24x trailing P/S on lumpy milestone revenue — but with a 50-petabyte proprietary dataset and over $500M of big-pharma cash already banked — WATCHLIST: the platform is the strongest of its cohort, yet a 24x entry must de-rate as revenue compounds, capping the 10-year bull case near 13x; wait for a Pattern B/E dip toward $2 or proof that proprietary-pipeline revenue is replacing milestone lumpiness.

At 6.2x trailing / 4.7x forward P/S and 48% off its 52-week high, with GAAP profitability, 14.7M members growing 35%, and Q1 2026 revenue +43% — WATCHLIST because the framework's headline pillar is structurally unmet: this is an exceptional operator-led story, not a founder-led one, and the lending-heavy balance sheet caps multiple expansion as the model matures toward a bank; it turns BUY on a dip toward the ~$14 52-week-low zone (≈5x trailing, ≈4x forward) or a clearer fee-and-tech-platform mix shift that de-risks the lending concentration.

At 4.5x trailing P/S with Q1 revenue +27% YoY (vs +19% guide), FY26 guidance raised, and a $250M buyback authorised — the Q1 execution trigger has fired; the 10-year multibagger math comfortably clears the framework's 10x aim, with Chauffeur L3 launching at Audi in 2027 as the next catalyst.

At 13x trailing P/S the market is already pricing in the bull-case exit multiple — WATCHLIST until valuation compresses; $22.7B backlog, founder voting control ~90%, and Q2 GAAP profitability mark this as a great company at a stretched entry, with a clean buy zone opening below ~$40.

At 1.8x trailing P/S on gross revenue less network fees with the stock down 61% from $107, Q1 delivering +32% revenue and +39% adjusted EBITDA, and the 10-year bull math meeting the framework's 10x aim — WATCHLIST while founder Jared Isaacman's transition to NASA reshapes Pillar 2 under new CEO Taylor Lauber; convert to BUY on one or two quarters of post-Up-C-collapse execution evidence or a further dip toward $35.

At 3.7x trailing P/S with first full-year GAAP profitability achieved and Platform revenue accelerating to +28% in Q1 2026 — WATCHLIST while the post-earnings rally cools; the 10-year bull-case math approaches but doesn't comfortably exceed the 10x aim, so wait for sub-$95 (P/S below 3x) or a Pattern B/E dip before initiating.

At 4.7x trailing P/S after a 14% earnings-day drop, with FCF growing 4x faster than revenue and operating margin at a Q1 record — WATCHLIST while the guidance overhang plays through; the 10-year bull-case math already meets the 10x aim at current price and 13x+ at $360 entry.

Excellent financials and a real AI pivot, but 4-5% revenue growth against Microsoft Teams and Google Meet caps this at a value-compounder thesis — not a 10-100x platform.

Trading at ~1.0x P/S with $776M net cash ≈ 92% of market cap — but guidance suspension, platform-dependency risk, and an active securities class action warrant waiting for Q2 evidence of CAC stabilisation before entering.

ARR accelerating to 25% while the stock is down 56% from peak — a classic narrative-collapse divergence in a leader of the $96B zero-trust market, with record 22% non-GAAP margins and $3.5B cash on hand.

Exceptional platform quality and founder-led execution at 48% revenue growth, but trailing P/S of 8.0x remains above the disciplined entry threshold — wait for compression toward 5-6x for a conviction entry.

The strongest network-effect moat in consumer technology combined with Zuckerberg's 61% voting control and AI-driven advertising acceleration justifies a BUY despite the 8x P/S — the capex surge is a bet, not a bleed, and the early returns are already visible in the numbers.

Exceptional business quality at 5.1x P/S after a 23% drawdown — but a non-founder CEO with modest equity and a market cap that structurally limits 10x potential keeps this in watchlist territory pending deeper multiple compression or a confirmed AI re-rating catalyst.

At $180 — down 60% from its 52-week high — Coinbase's dominant US exchange position, expanding everything-exchange TAM, and $11.3B fortress balance sheet offer an asymmetric entry into the world's most important crypto-financial infrastructure platform.

At 3.8x trailing P/S with 221M monthly uniques, first full year of GAAP profitability, and rentals growing 39% — the category leader trades at a macro-driven discount to its platform quality and AI optionality.

At 4.3x trailing P/S with $770M in cash, non-GAAP profitability achieved, and Purple AI accelerating attach — the valuation discount to the platform quality has become too wide to ignore.

At 2.1× P/S on 36% revenue growth and $1.6B net income, the market is pricing permanent disruption into a platform that just delivered its strongest year on record.

At 1.0× P/S, Korea's dominant e-commerce flywheel is priced for permanent decline; the data-incident overhang and leadership transition are recoverable setbacks in a structurally intact monopoly.

At 3.1× P/S with AWS re-accelerating to 24% growth and $80B in operating profit, Amazon offers exceptional quality at an unusually compressed valuation — the AI capex cycle is building the moat, not just spending the balance sheet.

GTA6 is a genuine revenue inflection, but the stock is pricing in success and Zelnick's PE-background management and $3B debt load limit conviction for long-horizon compounding.

Extraordinary valuation compression creates a compelling setup, but a credible path to GAAP profitability must materialise before conviction warrants a full BUY.

Exceptional business quality with a genuine data moat and strong founder alignment — but at ~11x P/S the entry is not yet asymmetric. Watch for a pullback toward sub-7x P/S or wait for forward multiples to compress through continued growth.

The only US company operating commercial driverless long-haul trucks, with a validated AI flywheel and elite founder control — but the $7.6B market cap is priced for 2028–2029 revenue that remains to be proven at scale, and ongoing dilution tempers near-term entry conviction.

At 4.5x P/S with the stock down 25% from its 52-week high and the company delivering its first full-year profit, Grab offers a rare combination of platform dominance, founder control, and a genuinely asymmetric entry price.

Exceptional founder-led thesis and regulatory moat, but pre-revenue with $430–550M annual burn — wait for first commercial power delivery before sizing a full position.

Compelling data flywheel and founder execution, but P/S of 6x sits above the entry threshold — build a position on dips toward $30–35.

Founder-led with compelling P/S entry and strong balance sheet, but a sharp deceleration to 9–10% revenue growth demands proof that Maestro can relight the flywheel before this becomes a BUY.

Exceptional business with durable moat and accelerating AI flywheel — but P/S of 8x and the absence of founder leadership keep this on the watchlist until valuation corrects further.

Revenue accelerating to 61% guided growth in 2026, gross loss ratios at record lows, and a structural reinsurance cession reduction from 55% to 20% unlocking major margin expansion — the forward P/S of 3.5x is compelling for patient capital.

FDA-resolved regulatory overhang, P/S under 2x, and a 70% drawdown from peak create an asymmetric entry into a profitable, founder-controlled platform building the infrastructure for AI-driven personalized medicine.

Founder-led, profitable, and AI-native at a historically compressed 4.3x P/S after an 80% drawdown — the risk/reward is compelling for patient capital.

Compelling flywheel at threshold valuation — add on further weakness toward $12–13.

Compelling AI-native lending platform now trading at 2.5x revenue after a sentiment-driven collapse — FY2025 profitability and 35% three-year growth guidance create an asymmetric entry point for patient capital.

Exceptional profitability and founder leadership, but decelerating growth and unclear expansion catalysts keep it off the buy list at current valuation.

Founder-controlled fintech compounding at 52% annually, GAAP profitable at scale, and down 53% from peak on cyclical crypto-revenue fears with a P/E of just 40× on record earnings

At 80× forward revenue and 110× forward earnings on FY2026 guidance, the valuation structurally prevents a positive 10-year return at any reasonable growth assumption

Exceptional financials and founder alignment undercut by a single structural fragility: ~50% traffic dependence on Google's algorithm

Founder-controlled platform with exceptional growth metrics, deep AI flywheel, and a child-safety overhang creating a rare entry window

Compelling AV platform thesis but valuation elevated and competitive risk not yet resolved

Strongest monopoly score in AI infrastructure, but P/S of ~21 and a $4.2T market cap make 10x returns over a decade mathematically demanding.

Strong flywheel thesis and 18-quarter beat-and-raise execution, but GAAP profitability is nascent, SBC drag is material, and valuation at ~3.1× FY2025 revenue leaves modest margin of safety at current price.

Spotify is the undisputed global audio platform with genuine network effects and a rapidly improving margin profile. At P/S ~5.1× (down 39% from all-time high), it is approaching but not yet at the framework's entry threshold. The structural royalty ceiling permanently limits margin upside vs. pure software peers. Initiate a starter position now and DCA aggressively toward P/S ~4×.

Compelling 10-year physical AI vision undermined by a P/S of ~14.6× (nearly 3× above the entry threshold), declining revenue, and a CEO distraction risk the board has not structurally addressed — the thesis is directionally right, the entry point is not.